➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
Express Scripts
Moodys
McKesson

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Details for Patent: RE44599

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE44599
Title:Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Abstract: Compounds that inhibit P13K.delta. activity, including compounds that selectively inhibit P13K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K.delta. plays a role in leukocyte function, using the compounds also are disclosed.
Inventor(s): Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Kirkland, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA)
Assignee: ICOS Corporation (Indianapolis, IN)
Application Number:13/730,276
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent RE44599

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No   Start Trial   Start Trial FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA   Start Trial
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 RX Yes No   Start Trial   Start Trial FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL   Start Trial
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes   Start Trial   Start Trial FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL   Start Trial
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-002 Jul 23, 2014 RX Yes Yes   Start Trial   Start Trial FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE44599

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005245875   Start Trial
Australia 2009230739   Start Trial
Canada 2566609   Start Trial
China 101031569   Start Trial
China 102229609   Start Trial
Cyprus 1118493   Start Trial
Cyprus 1118516   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Express Scripts
Dow
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.